Cargando…
No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy
Spasticity and muscle weakness is common in children with cerebral palsy (CP). Spasticity can be treated with botulinum neurotoxin-A (BoNT-A), but this drug has also been reported to induce muscle weakness. Our purpose was to describe the effect on muscle strength in the lower extremities after BoNT...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052872/ https://www.ncbi.nlm.nih.gov/pubmed/27766077 http://dx.doi.org/10.3389/fnhum.2016.00506 |
_version_ | 1782458305197637632 |
---|---|
author | Eek, Meta N. Himmelmann, Kate |
author_facet | Eek, Meta N. Himmelmann, Kate |
author_sort | Eek, Meta N. |
collection | PubMed |
description | Spasticity and muscle weakness is common in children with cerebral palsy (CP). Spasticity can be treated with botulinum neurotoxin-A (BoNT-A), but this drug has also been reported to induce muscle weakness. Our purpose was to describe the effect on muscle strength in the lower extremities after BoNT-A injections in children with CP. A secondary aim was to relate the effect of BoNT-A to gait pattern and range of motion. Twenty children with spastic CP were included in the study, 8 girls and 12 boys (mean age 7.7 years). All were able to walk without support, but with increased muscle tone interfering with motor function and gait pattern. Sixteen children had unilateral spastic CP and four bilateral spastic CP. Twenty-four legs received injections with BoNT-A in the plantar flexor muscles. The children were tested before treatment, around 6 weeks after at the peak effect of BoNT-A, and at 6 months after treatment, with measurement of muscle strength, gait analysis, and range of motion. There were no differences in muscle strength in plantar flexors of treated legs at peak effect compared to baseline. Six months after treatment, there was still no change in untreated plantar flexor muscles, but an increasing trend in plantar flexor strength in legs treated with BoNT-A. Parents reported positive effects in all children, graded as: small in three children, moderate in eight, and large in nine children. The gait analysis showed a small improvement in knee extension at initial contact, and there was a small increase in passive range of motion for ankle dorsiflexion. Two children had a period with transient weakness and pain. We found that voluntary force production in plantar flexor muscles did not decrease after BoNT-A, instead there was a trend to increased muscle strength at follow-up. The increase may be explained as an effect of the blocking of involuntary nerve impulses, leading to an opportunity to using and training the muscles with voluntary control. Adequate muscle strength is important for maintaining the ability to walk and knowledge of how a treatment affects muscle strength is useful when selecting interventions. |
format | Online Article Text |
id | pubmed-5052872 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50528722016-10-20 No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy Eek, Meta N. Himmelmann, Kate Front Hum Neurosci Neuroscience Spasticity and muscle weakness is common in children with cerebral palsy (CP). Spasticity can be treated with botulinum neurotoxin-A (BoNT-A), but this drug has also been reported to induce muscle weakness. Our purpose was to describe the effect on muscle strength in the lower extremities after BoNT-A injections in children with CP. A secondary aim was to relate the effect of BoNT-A to gait pattern and range of motion. Twenty children with spastic CP were included in the study, 8 girls and 12 boys (mean age 7.7 years). All were able to walk without support, but with increased muscle tone interfering with motor function and gait pattern. Sixteen children had unilateral spastic CP and four bilateral spastic CP. Twenty-four legs received injections with BoNT-A in the plantar flexor muscles. The children were tested before treatment, around 6 weeks after at the peak effect of BoNT-A, and at 6 months after treatment, with measurement of muscle strength, gait analysis, and range of motion. There were no differences in muscle strength in plantar flexors of treated legs at peak effect compared to baseline. Six months after treatment, there was still no change in untreated plantar flexor muscles, but an increasing trend in plantar flexor strength in legs treated with BoNT-A. Parents reported positive effects in all children, graded as: small in three children, moderate in eight, and large in nine children. The gait analysis showed a small improvement in knee extension at initial contact, and there was a small increase in passive range of motion for ankle dorsiflexion. Two children had a period with transient weakness and pain. We found that voluntary force production in plantar flexor muscles did not decrease after BoNT-A, instead there was a trend to increased muscle strength at follow-up. The increase may be explained as an effect of the blocking of involuntary nerve impulses, leading to an opportunity to using and training the muscles with voluntary control. Adequate muscle strength is important for maintaining the ability to walk and knowledge of how a treatment affects muscle strength is useful when selecting interventions. Frontiers Media S.A. 2016-10-06 /pmc/articles/PMC5052872/ /pubmed/27766077 http://dx.doi.org/10.3389/fnhum.2016.00506 Text en Copyright © 2016 Eek and Himmelmann. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neuroscience Eek, Meta N. Himmelmann, Kate No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title | No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title_full | No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title_fullStr | No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title_full_unstemmed | No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title_short | No Decrease in Muscle Strength after Botulinum Neurotoxin-A Injection in Children with Cerebral Palsy |
title_sort | no decrease in muscle strength after botulinum neurotoxin-a injection in children with cerebral palsy |
topic | Neuroscience |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052872/ https://www.ncbi.nlm.nih.gov/pubmed/27766077 http://dx.doi.org/10.3389/fnhum.2016.00506 |
work_keys_str_mv | AT eekmetan nodecreaseinmusclestrengthafterbotulinumneurotoxinainjectioninchildrenwithcerebralpalsy AT himmelmannkate nodecreaseinmusclestrengthafterbotulinumneurotoxinainjectioninchildrenwithcerebralpalsy |